108 related articles for article (PubMed ID: 3496854)
1. [Antitumor action of interleukin 2 and its biological activities].
Hamuro J
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2111-8. PubMed ID: 3496854
[TBL] [Abstract][Full Text] [Related]
2. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
[TBL] [Abstract][Full Text] [Related]
5. [Transfer of interleukin 2-activated lymphocytes].
Kohgo Y
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2127-34. PubMed ID: 3496856
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin-2 and cancer treatment].
Taguchi T
Gan To Kagaku Ryoho; 1986 Jan; 13(1):1-10. PubMed ID: 3510586
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
8. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
9. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
10. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
12. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
13. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2.
Greenberg PD; Cheever MA
J Biol Response Mod; 1984 Oct; 3(5):455-61. PubMed ID: 6239012
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
15. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.
Hefeneider SH; Conlon PJ; Henney CS; Gillis S
J Immunol; 1983 Jan; 130(1):222-7. PubMed ID: 6600178
[TBL] [Abstract][Full Text] [Related]
16. [Interleukin 2].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1203-7. PubMed ID: 3495239
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
18. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
19. [Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1884-9. PubMed ID: 3496050
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
